3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Neurotoxicity Syndromes
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphohistiocytosis, Hemophagocytic
1
Lymphatic Diseases
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Epstein-Barr Virus Infections
1
Colorectal Neoplasms
1
Interventions
Cyclophosphamide
29
fludarabine phosphate
22
Whole-Body Irradiation
20
Mycophenolic Acid
20
fludarabine
19
asciminib
19
nilotinib
16
Tacrolimus
13
Imatinib Mesylate
13
Melphalan
11
Dasatinib
9
Sirolimus
8
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
Granulocyte Colony-Stimulating Factor
7
Busulfan
7
bosutinib
6
Mesna
6
Cyclosporine
6
ponatinib
5
Stem Cell Transplantation
5
Filgrastim
5
venetoclax
4
ruxolitinib
4
blinatumomab
4
Specimen Handling
4
Cyclosporins
4
thymoglobulin
3
Bone Marrow Transplantation
3
Antilymphocyte Serum
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
AP 1903 reagent
×
1 year
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled